iBio, Inc. (NYSE AMEX: IBIO) today announced the engagement of CBR International Corporation (CBR) for strategic regulatory and clinical services to advance iBio’s Orphan Drug designated, plant-produced human alpha galactosidase A (“α-Gal A”) enzyme candidate for development as a therapeutic option for patients with Fabry disease.
“We expect this engagement to significantly accelerate our path to the clinic for this important product application of our platform technology,” said Robert Erwin, President of iBio. “CBR managed the successful application for Orphan Drug designation of plant-made α-Gal A, and has substantial experience in this field. They will join the team comprising our regular research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology and our manufacturing partner, Kentucky Bioprocessing, LLC.”
This Fabry disease therapeutic program is part of iBio’s broader program to bring forward approximately ten more candidate proteins for commercialization as “biosimilar” or “biobetter” therapeutic products. iBio intends to advance these candidates at least to a point sufficient to demonstrate the advantages of making them using the iBioLaunch™ platform technology and then enter into collaborative arrangements with industry partners. iBio already has demonstrated the applicability of its platform technology to most therapeutic protein classes, ranging from cytokines and growth factors to enzymes and antibodies.
Dr. Jeanne Novak, President and CEO of CBR commented, “Enzyme replacement therapy has been constrained by production limitations, interruptions and treatment cost. Patients with Fabry disease who do not receive enzyme replacement therapy are at increased risk of strokes, heart attack, heart disease, and renal failure. iBio’s innovative platform technology promises to add greater capacity for the supply of therapeutic protein biologics so that α-Gal A and other critical enzymes can be made available to more patients who need them in the future. We are confident that CBR’s clinical and regulatory expertise and extensive prior experience with α-Gal A will help expedite the development of iBio’s Fabry disease product program.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV